Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

about

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

Item

http://www.wikidata.org/entity/Q47822162

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@en

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@nl

type

Item

label

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@en

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@nl

prefLabel

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@en

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@nl

P1476

Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma.

@en

P2093

Hidenobu Tanihara

http://www.w3.org/2001/XMLSchema#string

P2860

Vasodilator actions of HA1077 in vitro and in vivo putatively mediated by the inhibition of protein kinase

The effect of Rho-associated protein kinase inhibitor on monkey Schlemm's canal endothelial cells.

Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.

Ripasudil: first global approval.

Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.

Shear stress-triggered nitric oxide release from Schlemm's canal cells

The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway.

RhoA GTPase-induced ocular hypertension in a rodent model is associated with increased fibrogenic activity in the trabecular meshwork.

p38 MAP kinase inhibitor suppresses transforming growth factor-β2-induced type 1 collagen production in trabecular meshwork cells.

Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.

P304

1669-1673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1378344

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Toshihiro Inoue

P577

2017-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28893104

http://www.w3.org/2001/XMLSchema#string